In this Q&A, Randa Wahid of Indero, and Lyn Mursalo, a freelance clinical research professional, share how sponsors and CROs ...

Estimated median progression free survival (PFS) in third-line treatment (180 mg dose) was 5.6 months. The comparable PFS threshold in standard of care treatments is 2.5 months 1.

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in ...

According to the investment banking (IB) industry, MEDIPOST is currently seeking to attract 100 billion–150 billion won in ...

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common ...

MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies ...

HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / ...

Global medical device CRO market size was worth around USD 8.24 billion in 2024 and is predicted to grow to around USD 19.69 billion by 2034, (CAGR) of 9.10%. The global medical device CRO market size ...

The Phase 1 trial was partially supported by a grant from the National Institutes of Health (NIH). During the trial, Trethera ...

Researchers from the University of Oklahoma Health Campus have published an article in the New England Journal of Medicine ...

Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors ...

Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.